The clinical effectiveness and cost-effectiveness of riluzole for motor neurone disease: a rapid and systematic review.

Antony Stewart was the main author. He designed the protocol and piloted and modified the forms used for assessment of eligibility, validity and data extraction. He undertook searches for studies and requested further information from authors. He liaised with content experts in the field to obtain background information and support. He assessed studies for eligibility, validity and extracted data from them. He collated the data and wrote the report. Amanda Burls was the main editor. She advised on the protocol for the review. She assessed studies for their eligibility, validity and independently extracted data from them. She read and commented on the draft report. Josie Sandercock provid ed statistical advice, independently extracted data on clinical effectiveness from the studies involved in this review. She contributed to the clinical effectiveness sections of the results. She read and commented on the draft report. Stirling Bryan provided health economics advice, and carried out economic modelling. He contributed to the health economics section. He read and commented on the draft report. Chris Hyde advised on the protocol for the review and contributed to the discussion and conclusions section. He read and commented on the draft report. have no pecuniary relationship with companies making or promoting the use of riluzole. ACKNOWLEDGEMENTS The authors acknowledge the help received from the advisory group of experts, who also acted as peer reviewers. ABBREVIATIONS ALAT Alanine aminotransferase ALS Amyotrophic lateral sclerosis ALSFRS ALS functional rating scale ASAT Aspartame aminotransferase BD, BID Twice a day BDNF Brain derived neurotrophic factor CBA Cost-benefit analysis CEA Cost-effectiveness analys is CIs Confidence intervals (95%) CUA Cost-utility analysis DARE Database of Abstracts of Reviews of Effectiveness ECG Electrocardiogram EMEA European Medicines Evaluation Agency EQ-5D EuroQol quality of life measurement instrument FVC Forced vital capacity GOT Glutamic-oxaloacetic transaminase GPT Glutamic-pyruvic transaminase HR Hazard ratio HTA Health Technology Assessment (also The NHS Health Technology Assessment database) ICER Incremental cost-effectiveness ratio ITT Intention to treat MND Motor neurone disease MVIC Maximal voluntary isometric contraction NHS EED NHS Economic Evaluations Database NICE National Institute for Clinical Excellence OD Once a day OR Odds ratio QALY Quality adjusted life year, used in cost-utility analysis QD, QDS Four times a day RCT Randomised controlled trial RBC Red blood cell count SD Standard deviation SEM Standard error of the mean SF12 Quality of life questionnaire (SF = short form; number denotes number of questions asked) SIP Sickness Impact Profile SPC Summary …